CFO
DYN icon

CVA Family Office’s Dyne Therapeutics DYN Stock Holding History

CVA Family Office’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133 Buy
+6
New +$112 ﹤0.01% 1780
2024
Q4 		– Sell
-12
Closed -$431 – 1304
2024
Q3 		$431 Buy
+12
New +$478 ﹤0.01% 1241

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

CVA Family Office's DYN Position: Q2 2026 in Review

CVA Family Office opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 6 shares worth $133. The stake represents ﹤0.01% of the portfolio and ranks #1780 among its holdings. This is a return to the name: CVA Family Office previously reported a position in DYN as recently as Q3 2024.

CVA Family Office first reported a position in DYN in Q3 2024 and has held it in 2 quarters since. The position peaked at $431 in Q3 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • CVA Family Office held 6 shares of Dyne Therapeutics worth $133 as of Q2 2026.
  • Dyne Therapeutics was a new CVA Family Office position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1780 holding.
  • CVA Family Office first reported a position in Dyne Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • CVA Family Office's Dyne Therapeutics position peaked at $431 in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.